Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
BACKGROUND
Sorafenib and sunitinib, novel anti-tumor agents approved for the treatment of renal cell carcinoma, have been associated with multiple adverse cutaneous effects.


OBJECTIVE
To further investigate the constellation of possible adverse effects of sorafenib and sunitinib on the skin.


METHODS
Case report of a 62 year old male with history of renal cell carcinoma treated with adjuvant sorafenib.


RESULTS
Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib.


CONCLUSIONS
Further investigation regarding the possible adverse cutaneous effects of sorafenib and sunitinib, pathogenesis and risk factors for development, associated time course, and preventative and therapeutic methods, will allow for better patient and physician education.
Sahai
Seema
S
Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. seema-sahai@uiowa.edu
Swick
Brian L
BL
D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004890:Erythema / Q000139:chemically induced*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D017444:Skin Diseases, Papulosquamous / Q000139:chemically induced*; D000077157:Sorafenib; D013280:Stomatitis / Q000139:chemically induced*
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib